<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7344800\results\search\testTrace\results.xml">
  <result pre="the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract The" exact="diagnosis" post="of Zika virus infection is complicated and includes testing"/>
  <result pre="(CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract The diagnosis of Zika virus" exact="infection" post="is complicated and includes testing for nucleic acids and"/>
  <result pre="The diagnosis of Zika virus infection is complicated and includes" exact="testing" post="for nucleic acids and IgM and IgG antibodies, depending"/>
  <result pre="stage of infection. Zika IgG is an important marker of" exact="infection" post="after the acute stage; however, IgG assays can lack"/>
  <result pre="endemic regions, and specificity only was assessed in 1685 blood" exact="screening" post="and diagnostic samples from Zika non-endemic regions. Cross-reactivity was"/>
  <result pre="samples from both prevalent and non-endemic regions. Zika virus serology" exact="diagnosis" post="immunoglobulin sensitivity specificity 1. Introduction The Zika virus (ZIKV)"/>
  <result pre="from the same forest [2]. The first human case of" exact="infection" post="with ZIKV occurred in Uganda in 1962â€&quot;3 [3]. Recently,"/>
  <result pre="emergence of new ZIKV epidemics in urban areas [9]. ZIKV" exact="infection" post="is asymptomatic in an estimated 80% of cases [10,11,12]."/>
  <result pre="in an estimated 80% of cases [10,11,12]. When symptomatic, ZIKV" exact="infection" post="usually presents with non-specific influenza-like symptoms, including rash, fever,"/>
  <result pre="(DENV), Chikungunya, and West Nile virus [9]. Complications of ZIKV" exact="infection" post="include Guillainâ€&quot;BarrÃ© syndrome, a neurologic disorder that can lead"/>
  <result pre="that can lead to paralysis and death [9]. Pre-natal ZIKV" exact="infection" post="can cause serious neurologic sequelae including, but not limited"/>
  <result pre="intracranial calcifications, and ocular abnormalities [8]. Laboratory evidence of ZIKV" exact="infection" post="can be obtained by testing clinical samples (biofluids and"/>
  <result pre="[8]. Laboratory evidence of ZIKV infection can be obtained by" exact="testing" post="clinical samples (biofluids and tissue) for viral nucleic acid"/>
  <result pre="nucleic acid or virus-specific IgM and IgG antibodies [12]. Serologic" exact="testing" post="is recommended in individuals if the specimen is collected"/>
  <result pre="considerable degree of structural homology with other flaviviruses [15,16]. Serology-based" exact="diagnosis" post="has historically posed a challenge due to the well-known"/>
  <result pre="neither vaccines to prevent Zika nor effective drugs for the" exact="treatment" post="of already infected patients [17]. Improvements in the surveillance"/>
  <result pre="patients [17]. Improvements in the surveillance and monitoring of Zika" exact="infection" post="would support the efforts to combat this viral infection"/>
  <result pre="Zika infection would support the efforts to combat this viral" exact="infection" post="[17]. Due to the similarity of ZIKV to other"/>
  <result pre="ElecsysÂ® Zika IgG assay, a qualitative one-step double-antigen sandwich (DAGS)" exact="immunoassay" post="using recombinant ZIKV antigens, designed for the in vitro"/>
  <result pre="immunoassay using recombinant ZIKV antigens, designed for the in vitro" exact="detection" post="of anti-Zika IgG antibodies in human serum and plasma,"/>
  <result pre="antibodies in human serum and plasma, using samples from: ZIKV" exact="prevalence" post="areas, blood donors from Europe, pregnant women from Europe,"/>
  <result pre="was performed at TRIGA-S Scientific Solutions, Habach, Germany. All other" exact="testing" post="was performed at Roche Diagnostics GmbH (Penzberg, Germany). 2.2."/>
  <result pre="prevalent areas included patients from Latin America with suspected Zika" exact="infection" post="(N = 396) and patients in the CÃ´te dâ€™Ivoire"/>
  <result pre="of the ElecsysÂ® Zika IgG assay were determined using a" exact="testing" post="algorithm: the comparator serologic test, followed by further resolution"/>
  <result pre="immunoblot assay (MIKROGEN GmbH, Neuried, Germany; Figure 1) [19]. The" exact="testing" post="algorithm provided a surrogate standard for assessing diagnostic performance."/>
  <result pre="In total, 52 samples that were confirmed negative by resolution" exact="testing" post="were either reactive or borderline with the anti-Zika virus"/>
  <result pre="samples that were ElecsysÂ® Zika IgG negative but discrepant, further" exact="testing" post="found that 10 were positive for DENV IgG antibodies,"/>
  <result pre="3.1.2. Zika Non-Endemic Regions In 1685 routine diagnostic and blood" exact="screening" post="samples from Europe, the ElecsysÂ® Zika IgG assay had"/>
  <result pre="also in the interest of being able to detect historic" exact="infection" post="and to help predict future outbreaks of the disease"/>
  <result pre="blood, Zika IgG is particularly useful for mapping patterns of" exact="infection" post="and predicting future outbreaks and is used by the"/>
  <result pre="and physical propertiesTrans. R. Soc. Trop. Med. Hyg.19524652153410.1016/0035-9203(52)90043-612995441 3.SimpsonD.I.Zika virus" exact="infection" post="in manTrans. R. Soc. Trop. Med. Hyg.19645833533810.1016/0035-9203(64)90201-914175744 4.LoweR.BarcellosC.BrasilP.CruzO.G.HonÃ³rioN.A.KuperH.CarvalhoM.S.The Zika"/>
  <result pre="Health2018159610.3390/ijerph1501009629315224 5.SpiteriG.SudreB.SeptfonsA.BeautÃ©J.collab: The European Zika Surveillance NetworkSurveillance of Zika virus" exact="infection" post="in the EU/EEA, June 2015 to January 2017Eurosurveillance201722170025410.2807/1560-7917.ES.2017.22.41.17-0025429043960 6.PaixÄƒoE.S.TeixeiraM.G.RodriguesL.C.Zika,"/>
  <result pre="Virus InfectionsAvailable online: https://www.cdc.gov/zika/laboratories/types-of-tests.html(accessed on 2 January 2020) 22.LandryM.L.St GeorgeK.Laboratory" exact="diagnosis" post="of Zika virus infectionArch. Pathol. Lab. Med.2017141606710.5858/arpa.2016-0406-SA27763787 23.FritzellC.RoussetD.AddeA.KazanjiM.Van KerkhoveM.D.FlamandC.Current"/>
  <result pre="performance of commercial IgM and IgG enzyme-linked immunoassays (ELISAs) for" exact="diagnosis" post="of Zika virus infectionVirol. J.20181510810.1186/s12985-018-1015-630005683 26.SafronetzD.SloanA.SteinD.R.MendozaE.BararioN.RanandheeraC.ScharikowL.HollowayK.RobinsonA.Traykova-AndonovaM.et al.Evaluation of 5"/>
  <result pre="infants with microcephaly, Guinea-Bissau, 2016Emerg. Infect. Dis.2018294895010.3201/eid2405.18015329664391 Figure 1 Resolution" exact="testing" post="algorithm. tropicalmed-05-00097-t001_Table 1Table 1 ElecsysÂ® Zika IgG and anti-Zika"/>
  <result pre="Resolutionâ€ Sensitivity(95% CI) Specificity(95% CI) ElecsysÂ® Zika IgG Suspected Zika" exact="infection" post="from Latin America 396 284 55 36 21 93.11"/>
  <result pre="92.88 (89.42â€&quot;95.48) 100 (97.59â€&quot;100) Anti-Zika Virus ELISA IgG Suspected Zika" exact="infection" post="from Latin America 396 305 21 36 34 100.00"/>
 </snippets>
</snippetsTree>
